Literature DB >> 36264940

Three-dimensional fractal dimension and lacunarity features may noninvasively predict TERT promoter mutation status in grade 2 meningiomas.

So Yeon Won1,2, Jun Ho Lee3, Narae Lee4, Yae Won Park2, Sung Soo Ahn2, Jinna Kim2, Jong Hee Chang5, Se Hoon Kim6, Seung-Koo Lee2.   

Abstract

PURPOSE: The 2021 World Health Organization classification includes telomerase reverse transcriptase promoter (TERTp) mutation status as a factor for differentiating meningioma grades. Therefore, preoperative prediction of TERTp mutation may assist in clinical decision making. However, no previous study has applied fractal analysis for TERTp mutation status prediction in meningiomas. The purpose of this study was to assess the utility of three-dimensional (3D) fractal analysis for predicting the TERTp mutation status in grade 2 meningiomas.
METHODS: Forty-eight patients with surgically confirmed grade 2 meningiomas (41 TERTp-wildtype and 7 TERTp-mutant) were included. 3D fractal dimension (FD) and lacunarity values were extracted from the fractal analysis. A predictive model combining clinical, conventional, and fractal parameters was built using logistic regression analysis. Receiver operating characteristic curve analysis was used to assess the ability of the model to predict TERTp mutation status.
RESULTS: Patients with TERTp-mutant grade 2 meningiomas were older (P = 0.029) and had higher 3D FD (P = 0.026) and lacunarity (P = 0.004) values than patients with TERTp-wildtype grade 2 meningiomas. On multivariable logistic analysis, higher 3D FD values (odds ratio = 32.50, P = 0.039) and higher 3D lacunarity values (odds ratio = 20.54, P = 0.014) were significant predictors of TERTp mutation status. The area under the curve, accuracy, sensitivity, and specificity of the multivariable model were 0.84 (95% confidence interval 0.71-0.93), 83.3%, 71.4%, and 85.4%, respectively.
CONCLUSION: 3D FD and lacunarity may be useful imaging biomarkers for predicting TERTp mutation status in grade 2 meningiomas.

Entities:  

Mesh:

Substances:

Year:  2022        PMID: 36264940      PMCID: PMC9584385          DOI: 10.1371/journal.pone.0276342

Source DB:  PubMed          Journal:  PLoS One        ISSN: 1932-6203            Impact factor:   3.752


  34 in total

1.  Characterization and Impact of TERT Promoter Region Mutations on Clinical Outcome in Renal Cell Carcinoma.

Authors:  Jozefina Casuscelli; Maria F Becerra; Brandon J Manley; Emily C Zabor; Ed Reznik; Almedina Redzematovic; Maria E Arcila; Daniel M Tennenbaum; Mazyar Ghanaat; Mahyar Kashan; Christian G Stief; Maria Carlo; Martin H Voss; Darren R Feldman; Robert J Motzer; Yingbei Chen; Victor E Reuter; Jonathan A Coleman; Paul Russo; James J Hsieh; Abraham Ari Hakimi
Journal:  Eur Urol Focus       Date:  2017-09-24

2.  The implications of the heterogeneous distribution of Ki-67 labelled cells in meningiomas.

Authors:  H P Siegers; P Zuber; M F Hamou; G D van Melle; N de Tribolet
Journal:  Br J Neurosurg       Date:  1989       Impact factor: 1.596

3.  Telomerase activity and expression of the telomerase catalytic subunit, hTERT, in meningioma progression.

Authors:  M Simon; T W Park; S Leuenroth; V H Hans; T Löning; J Schramm
Journal:  J Neurosurg       Date:  2000-05       Impact factor: 5.115

4.  Distribution of TERT promoter mutations in pediatric and adult tumors of the nervous system.

Authors:  Christian Koelsche; Felix Sahm; David Capper; David Reuss; Dominik Sturm; David T W Jones; Marcel Kool; Paul A Northcott; Benedikt Wiestler; Katja Böhmer; Jochen Meyer; Christian Mawrin; Christian Hartmann; Michel Mittelbronn; Michael Platten; Benjamin Brokinkel; Marcel Seiz; Christel Herold-Mende; Andreas Unterberg; Jens Schittenhelm; Michael Weller; Stefan Pfister; Wolfgang Wick; Andrey Korshunov; Andreas von Deimling
Journal:  Acta Neuropathol       Date:  2013-10-24       Impact factor: 17.088

Review 5.  Telomerase targeted therapy in cancer and cancer stem cells.

Authors:  Yucheng Xu; Kaijie He; Amir Goldkorn
Journal:  Clin Adv Hematol Oncol       Date:  2011-06

Review 6.  Lung cancer-a fractal viewpoint.

Authors:  Frances E Lennon; Gianguido C Cianci; Nicole A Cipriani; Thomas A Hensing; Hannah J Zhang; Chin-Tu Chen; Septimiu D Murgu; Everett E Vokes; Michael W Vannier; Ravi Salgia
Journal:  Nat Rev Clin Oncol       Date:  2015-07-14       Impact factor: 66.675

7.  Preoperative identification of meningiomas that are highly likely to recur.

Authors:  S Nakasu; Y Nakasu; M Nakajima; M Matsuda; J Handa
Journal:  J Neurosurg       Date:  1999-03       Impact factor: 5.115

8.  Diffusion and perfusion MRI may predict EGFR amplification and the TERT promoter mutation status of IDH-wildtype lower-grade gliomas.

Authors:  Yae Won Park; Sung Soo Ahn; Chae Jung Park; Kyunghwa Han; Eui Hyun Kim; Seok-Gu Kang; Jong Hee Chang; Se Hoon Kim; Seung-Koo Lee
Journal:  Eur Radiol       Date:  2020-08-12       Impact factor: 5.315

9.  Clinical and diffusion parameters may noninvasively predict TERT promoter mutation status in grade II meningiomas.

Authors:  Ilah Shin; Yae Won Park; Sung Soo Ahn; Seok-Gu Kang; Jong Hee Chang; Se Hoon Kim; Seung-Koo Lee
Journal:  J Neuroradiol       Date:  2021-03-11       Impact factor: 3.447

10.  Mutation of the TERT promoter, switch to active chromatin, and monoallelic TERT expression in multiple cancers.

Authors:  Josh Lewis Stern; Dan Theodorescu; Bert Vogelstein; Nickolas Papadopoulos; Thomas R Cech
Journal:  Genes Dev       Date:  2015-10-29       Impact factor: 11.361

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.